Page 1,651«..1020..1,6501,6511,6521,653..1,6601,670..»

Memphis Researchers Planning Big Upgrades to Online Genetics Database – Memphis Daily News

Posted: Published on July 11th, 2017

VOL. 132 | NO. 135 | Monday, July 10, 2017 A pair of scientists in Memphis is using almost $2 million in grant money to make improvements to an online database and open-source software system called GeneNetwork, used by researchers to study genetic differences and evaluate disease risk. Drs. Robert Williams and Saunak Sen, both part of the faculty at the University of Tennessee Health Science Center, won a grant from the National Institutes of Health for the project. GeneNetwork was launched in 2001 as part of a NIH Human Brain Project grant to UTHSC and was one of the first websites designed for gene mapping. Williams, who chairs the Department of Genetics, Genomics and Informatics at UTHSC, said the grant money will be used to support major upgrades for the software infrastructure for gene mapping and analysis for the system. One of the systems main uses, he said, is being able to predict more accurate health outcomes from genetic and environmental data. The system itself is like a combination of Microsofts popular Excel spreadsheet software paired with large amounts of financial data. Except in this case, its biological rather than financial data, combined with a sophisticated spreadsheet that allows … Continue reading →

Posted in Genetics | Comments Off on Memphis Researchers Planning Big Upgrades to Online Genetics Database – Memphis Daily News

Getting tumors tested for genetics is the latest theory to help drugs target cancer – The Denver Post

Posted: Published on July 11th, 2017

Family photo provided by Katie Rosenbaum via AP WASHINGTON Colon cancer. Uterine cancer. Pancreatic cancer. Whatever the tumor, the more gene mutations lurking inside, the better chance your immune system has to fight back. Thats the premise behind the recent approval of a landmark drug, the first cancer therapy ever cleared based on a tumors genetics instead of the body part it struck first. Now thousands of patients with worsening cancer despite standard treatment can try this immunotherapy as long as genetic testing of the tumor shows theyre a candidate. Its like having a lottery ticket, said Johns Hopkins oncologist Dr. Dung Le, who helped prove the new use for the immunotherapy Keytruda. Weve got to figure out how to find these patients, because its such a great opportunity for them. Today, doctors diagnose tumors by where they originate breast cancer in the breast, colon cancer in the colon and use therapies specifically tested for that organ. In contrast, the Food and Drug Administration labeled Keytruda the first tissue-agnostic treatment, for adults and children. The reason: Seemingly unrelated cancers occasionally carry a common genetic flaw called a mismatch repair defect. Despite small studies, FDA found the evidence convincing that for … Continue reading →

Posted in Genetics | Comments Off on Getting tumors tested for genetics is the latest theory to help drugs target cancer – The Denver Post

Project to explore Angus genetics for northern production systems – Beef Central

Posted: Published on July 11th, 2017

THERE is growing interest in increasing Angus content of calves in Northern Australian beef herds in an effort to improve overall beef quality and to maximise the profitability of beef operations. This is most likely to occur through the use of Angus or Angus derived bulls (in natural mating or AI programs) over Bos indicus cows to produce crossbred progeny. For successful long-term infusion of Angus genetics, breeding strategies aimed at identifying and enhancing the adaptability of Angus genetics for Northern Australian production systems is vital. In a collaborative project, CSIRO and Angus Australia are exploring funding opportunities to undertake a project aimed at investigating the potential for DNA pooling, a cost-effective methodology applicable for use in large scale commercial herds, to identify Angus genetics suited to the production environment in Northern Australia, by estimating the contribution of individual sires to traits of interest (e.g. coat type, heat tolerance). The project would involve collecting phenotypes for traits related to adaptation and genomic profiles on 1000 Angus cross progeny bred in Northern Australia sired by registered Angus bulls. It is envisaged that information generated from this project will inform commercial producers when making important Angus bull selection decisions for Northern Australia. … Continue reading →

Posted in Genetics | Comments Off on Project to explore Angus genetics for northern production systems – Beef Central

Treatment in testing for sleep disorder commonly found in men with Parkinson’s or LBD – WNDU-TV

Posted: Published on July 10th, 2017

You may not have heard of it but R.E.M. sleep disorder is most common in men who also have Parkinsons disease, or Lewy body dementia. When most of us sleep, our bodies enter a state of muscle paralysis. People with R.E.M. sleep behavior disorder lose that, and are capable of acting out physical activity in their dreams, which can be violent. Orvis Rig Rigsby and his wife Karen loved theater and travel. Karen Rigsby He was a theater professor and I was a theater person, so for me it was reallythere was an immediate connection and we had a similar sense of humor and it was just a lot of fun," says Karen Rigsby. But just a few years ago, Rig started showing signs of dementia. He had an incident where he got very disoriented and lost in our backyard and thats when we started looking for help from a neurologist, says Karen. At first, Doctor Ira Goodman thought Rig had Alzheimers disease. And actually, I initially referred him for a clinical trial for Alzheimers disease but right before he entered I changed my mind, explains Dr. Goodman, who specializes in neurology. Instead, Doctor Goodman diagnosed Rig with Lewy body … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Treatment in testing for sleep disorder commonly found in men with Parkinson’s or LBD – WNDU-TV

Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s – Labiotech.eu (blog)

Posted: Published on July 10th, 2017

PrextonTherapeutics has launched a Phase II trial to test whether its drug foliglurax can treat the motor complications of standard levodopa therapy. The Phase II trial will enroll 165 patients across the UK, Germany, France, Austria, Spain and Italy to monitor the effects of Prextonsfoliglurax. The company is looking for patients that have been treated with standard levodopa therapy and are experiencing loss of efficacy and dyskinesia, i.e. uncontrolled movements. The trial, funded through Prextons 29M Series B this February, will compare the amount oftime during the day when the medication wears off and symptoms get worse. Traditional approaches like the administration of levodopa target dopaminergic neurons, whose activity is affected by Parkinsons. However, as the disease progresses the treatment wears off and motor complications appear. In order to circumvent these issues, Prextons foliglurax activates mGluR4 receptors in the glutamatergic neuronal system, which is not affected by PD and can compensate for the loss of function of the dopaminergic system. If successful, PrextonTherapeutics will have to compete in the Parkinsons market with Newron, whose drug Xadago wasapprovedearlier this year as the first drug for Parkinsonsin 11 years; as well as the Promethera and Roche team, which announced last week a … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s – Labiotech.eu (blog)

The FDA Approved the First New Sickle Cell Drug in 20 YearsBut It’s Not a Cure – Fortune

Posted: Published on July 10th, 2017

Magnified sickle cells.Photograph by Media for Medical UIG via Getty Images News that the Food and Drug Administration (FDA) approved the first new drug to treat sickle cell in nearly 20 years last Friday understandably drew cheers from patients and advocates who have stood by with bated breath for a breakthrough. But as laudable as the milestone may be, the treatment's limited reach underscores just how hard it is to create groundbreaking medicines which do little more than staunch certain symptoms. The FDA's latest approval is for Endari, a drug created by the under-the-radar biotech Emmaus Medical Inc. As the agency itself notes, Endari is no cure. Rather, it's approved to "reduce severe complications associated with the blood disorder," such as extreme side effects in the lungs and major pain. The drug also cut down patients' needs to go to a hospital for sickle-cell related pain compared with placebo in clinical trials. Click here to subscribe to Brainstorm Health Daily, our brand new newsletter about health innovations. This is all welcome news for people who suffer from the genetic blood disorder, whose various forms afflict some 100,000 Americans at any given time, according to the National Institutes of Health. But … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on The FDA Approved the First New Sickle Cell Drug in 20 YearsBut It’s Not a Cure – Fortune

Here’s Why PTC Therapeutics, Inc. Popped 45.2% in June … – Madison.com

Posted: Published on July 10th, 2017

What happened Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT), a biotech focused on RNA-based therapies, surged 45.2% higher in June, according to data from S&P Global Market Intelligence. Investors took the Food and Drug Administration's (FDA) decision to grant the company's muscular dystrophy candidate Translarna an independent advisory-committee review as a good sign. Normally, an advisory-committee meeting is bad news because it means the FDA wants second opinions before issuing a decision about whether or not to approve a new drug candidate. However, this isn't Translarna's first rodeo. Image source: Getty Images. In February 2016, the FDA told PTC Therapeutics that its new drug application for Translarna was not sufficiently complete to permit a review. The experimental therapy is supposed to reduce the effect of nonsense mutations that lead to a lack of functional dystrophin, a crucial muscle-membrane protein, which, in turn, causes irreversible muscle damage. The FDA cited a lack of evidence proving Translarna works because PTC Therapeutics failed to prove a statistically significant benefit during clinical trials supporting the application. In theory, Translarna's nonsense-mutation-alleviating mechanism could play a role in other genetic diseases. Unfortunately, a failure to provide a significant benefit over a placebo among cystic fibrosis patients … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Here’s Why PTC Therapeutics, Inc. Popped 45.2% in June … – Madison.com

US gastroenterologists views on ulcerative colitis drugs – The Pharma Letter (registration)

Posted: Published on July 10th, 2017

Results from a recent study just released by Spherix Global Insights reveal the views of US gastroenterologists To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever. BiosimilarsBiotechnologyEntyvioGastro-intestinalsHospiraInflectraJanssenJohnson & JohnsonMarkets & MarketingPfizerStelaraUlcerative colitisUSA Access The Pharma Letter's latest news free for 7 days PLUS... you can receive the Pharma Letter headlines and news roundup email free forever Click here to take a free trial Unlimited access to The Pharma Letter site for a whole year Only 77 per month or 820 per year Click here to subscribe The rest is here: US gastroenterologists views on ulcerative colitis drugs - The Pharma Letter (registration) … Continue reading →

Posted in Ulcerative Colitis | Comments Off on US gastroenterologists views on ulcerative colitis drugs – The Pharma Letter (registration)

Ulcerative Colitis Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2022 – satPRnews (press release)

Posted: Published on July 10th, 2017

Ulcerative Colitis Drugs Market report provides key statistics on the market status of the Ulcerative Colitis Drugs Manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Ulcerative Colitis Drugs Industry. The Ulcerative Colitis Drugs industry report firstly announced the Ulcerative Colitis Drugs Market fundamentals: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Get PDF Sample of Ulcerative Colitis Drugs Market Report @ https://www.absolutereports.com/enquiry/request-sample/10732468 Ulcerative Colitis Drugs Market split by Application -Application 1, Application 2, Application 3 Ulcerative Colitis Drugs Market Segment by Regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China). Through the statistical analysis, the Ulcerative Colitis Drugs Market report depicts the global Industry Analysis, Manufacturers Analysis, Ulcerative Colitis Drugs Industry Development Trend, Sales Demand and Forecast to 2022. Table of Contents: Chapter 1 Ulcerative Colitis Drugs Market Overview 1.1 Definition 1.2 Classification Analysis 1.3 Application Analysis 1.4 Ulcerative Colitis Drugs Industry Chain Structure Analysis 1.5 Ulcerative Colitis Drugs Market Development Overview 1.6 Global Ulcerative Colitis Drugs Market Comparison Analysis 1.6.1 Global Import Market Analysis 1.6.2 Global Export Market Analysis 1.6.3 … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Ulcerative Colitis Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2022 – satPRnews (press release)

Crohn’s and Colon Surgery: Part 1, Getting Prepared – IBD News Today

Posted: Published on July 10th, 2017

I have learned that living with Crohns can be a daily battle. Thats why us Crohnies are known as warriors! Even though there are many medications available to treat Crohns, sometimes surgery is necessary. Although Crohns can affect anywhere in the digestive tract, the colon is the most commonly affected portion of intestines. Total colectomy involves removing the entire colon. Partial colectomy involves removing part of the colon. Otherterms for this surgery include bowel resection and subtotal colectomy. Hemicolectomy involves removing the right or left portion of the colon. Proctocolectomy is the removal of the entire colon and the rectum. Many diseases and conditions that affect the colon can become dangerous. These include, but are not limited to, bleeding in the intestine, bowel obstructions, colon cancer, Crohns disease, ulcerative colitis, diverticulitis, and preventative surgery. Many people fearhaving a colectomy because of the risk of needing a ostomy bag. It is very importing to listen to your doctors directions when preparing for colon surgery. This also goes with having resections in small intestines. Typically prep starts a couple days prior to surgery, and can include: Step 1. If youre taking medications, gettingoff medications that can get in the way of healing … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Crohn’s and Colon Surgery: Part 1, Getting Prepared – IBD News Today

Page 1,651«..1020..1,6501,6511,6521,653..1,6601,670..»